Karyopharm Therapeutics Inc. (KPTI) has a negative trailing P/E of -0.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -140.55%, forward earnings yield 40.98%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 41/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.2 | 0.27 | 2.17 | 2,287.93 | - |
| 2017 | -3.4 | 0.91 | 3.40 | 274.25 | - |
| 2018 | -3.0 | -0.25 | 2.90 | 17.53 | - |
| 2019 | -5.9 | -2.32 | 23.84 | 29.01 | - |
| 2020 | -5.7 | 0.37 | 22.04 | 10.30 | - |
| 2021 | -3.9 | 0.10 | -6.06 | 2.30 | - |
| 2022 | -1.7 | -0.08 | -16.71 | 1.77 | - |
| 2023 | -0.7 | 0.02 | -0.73 | 0.68 | - |
| 2024 | -1.1 | 0.02 | -0.44 | 0.57 | - |
| 2025 | -0.4 | 0.00 | -0.27 | 0.55 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.92 | $154K | $-109.58M | -71153.9% |
| 2017 | $-2.81 | $1.61M | $-128.98M | -8036.4% |
| 2018 | $-3.14 | $30.34M | $-178.41M | -588.1% |
| 2019 | $-3.22 | $40.89M | $-199.59M | -488.1% |
| 2020 | $-2.72 | $108.09M | $-196.27M | -181.6% |
| 2021 | $-1.65 | $209.82M | $-124.09M | -59.1% |
| 2022 | $-2.02 | $157.07M | $-165.29M | -105.2% |
| 2023 | $-1.25 | $146.03M | $-143.1M | -98% |
| 2024 | $-1.23 | $145.24M | $-76.42M | -52.6% |
| 2025 | $-17.93 | $146.07M | $-196.04M | -134.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.45 | $-6.02 – $-3.07 | $137.49M | $127.98M – $155.34M | 4 |
| 2027 | $-3.20 | $-5.35 – $-1.05 | $168.23M | $149.7M – $186.76M | 3 |
| 2028 | $-1.21 | $-2.24 – $-0.34 | $216.08M | $216.03M – $216.13M | 3 |
| 2029 | $3.58 | $3.14 – $4.17 | $352.31M | $318.53M – $397.07M | 1 |
| 2030 | $6.98 | $6.11 – $8.13 | $505.43M | $456.97M – $569.64M | 1 |
